JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $500 from $503 and keeps an Overweight rating on the shares. Alyftrek’s approval with a higher U.S. price than Trikafta sets the stage for continued Cystic Fibrosis revenue growth in 2025, says the analyst following the “ahead-of-schedule but widely-expected approval.” The firm sees an attractive buying opportunity created by suzetrigine’s “underwhelming” Phase 2 results and views the stock as “likely to work higher in 2025 with two key launches and multiple potential pipeline updates,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Gains FDA Approval for Cystic Fibrosis Drug
- Vertex announces FDA approval of Alyftrek
- Vertex announces FDA exands approval for Trikafta
- Channel Therapeutics highlights difference between NaV1.7, NaV1.8
- Vertex Pharmaceuticals price target lowered to $520 from $566 at BMO Capital